Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Honeycomb: Radiprodil in GRIN-related disorder
NCT05818943Phase 1Active, not recruiting
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of radiprodil in GRIN-related disorder, sponsored by GRIN Therapeutics, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Maximum Plasma concentration of radiprodil at Week 20 and 4 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
radiprodil
03
Conditions
GRIN-related disorder
Beyond the preview
Go deeper on NCT05818943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818943.